In preclinical and clinical studies, ex-vivo generated IL-10-producing regulatory lymphocytes have been shown to ameliorate GVHD in mice and human but major obstacles to clinical use of Tregs include the high dose of Treg cells required and difficulty of producing large amounts of Tregs ex-vivo66, 67. Here, IL10 is linked to graft versus host disease.